Grown Rogue International (GRUSF) Capital Leases (2017 - 2026)
Grown Rogue International's (GRUSF) quarterly Capital Leases came in at $51359.0 in Q1 2026, down 24.23% quarter-over-quarter from $67782.0 in Q4 2025.
Grown Rogue International (GRUSF) Capital Leases (2017 - 2026) Analysis & Trends
Grown Rogue International's Capital Leases history runs 6 years deep, the most recent figure standing at $51359.0 for Q1 2026.
- On a quarterly basis, Capital Leases changed N/A year-over-year to $51359.0 in Q1 2026; TTM through Mar 2026 was $51359.0, a N/A change from a year earlier, with the FY2025 full-year figure at $67782.0, changed N/A from the prior year.
- Capital Leases fell to $51359.0 in Q1 2026 per GRUSF's latest filing, from $67782.0 in the prior quarter.
- Across five years, Capital Leases topped out at $67782.0 in Q4 2025 and bottomed at $51359.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51,359.00 |
| Dec 31, 2025 | 67,782.00 |
| Jul 31, 2020 | 72,908.00 |
| Apr 30, 2020 | 95,087.00 |
| Jan 31, 2020 | 104,130.00 |
| Oct 31, 2019 | 129,876.00 |
| Jul 31, 2019 | 138,162.00 |
| Apr 30, 2019 | 136,767.00 |
| Jan 31, 2019 | 103,371.00 |
| Oct 31, 2018 | 99,134.00 |
| Apr 30, 2018 | 149,321.00 |
| Oct 31, 2017 | 82,810.00 |